Jefferies analyst Akash Tewari raised the firm’s price target on Regeneron (REGN) to $937 from $935 and keeps a Buy rating on the shares after the company and partner Sanofi (SNY) announced positive results from the second Phase 3 trial for Dupixent in chronic obstructive pulmonary disease, or COPD. The firm’s peak sales estimate for Dupixent in COPD come in at about $3.7B and total worldwide peak sales for all indications come in at about $19.5B, which it notes is generally in line with consensus.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron, Sanofi report Dupixent reduced COPD exacerbations in second trial
- Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
- Regeneron Announces Investor Conference Presentation
- Regeneron commits $34M over five years to sponsor science & engineering fair
- Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
